Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 13/20 | 0.42 |
| ▸ | MKNK2 | Q9HBH9 | 4/20 | 0.41 |
| ▸ | CDK8 | P49336 | 1/20 | 0.40 |
| ▸ | ABL2 | P42684 | 6/20 | 0.39 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.39 |
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.39 |
| ▸ | BCR | P11274 | 2/20 | 0.39 |
| ▸ | SRC | P12931 | 3/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20227782 | 0.89 | ABL1 (0.47) | ABL1MKNK2CDK8ABL2FGFR4 | |
| SCHEMBL19307233 | 0.85 | ABL1 (0.49) | ABL1MKNK2CDK8ABL2FGFR4 | |
| SCHEMBL29614814 | 0.85 | ABL1 (0.49) | ABL1MKNK2CDK8ABL2FGFR4 | |
| SCHEMBL20214778 | 0.85 | ABL1 (0.52) | ABL1MKNK2CDK8ABL2FGFR4 | |
| SCHEMBL20214661 | 0.81 | ABL1 (0.46) | ABL1MKNK2CDK8ABL2FGFR4 | |
| SCHEMBL23732874 | 0.78 | ABL1 (0.44) | ABL1MKNK2CDK8ABL2FGFR4 | |
| SCHEMBL20227767 | 0.77 | ABL1 (0.46) | ABL1MKNK2CDK8ABL2FGFR4 | |
| SCHEMBL20227766 | 0.76 | ABL1 (0.46) | ABL1MKNK2CDK8ABL2FGFR4 | |
| SCHEMBL20214708 | 0.76 | ABL1 (0.45) | ABL1MKNK2CDK8ABL2FGFR4 | |
| SCHEMBL21351228 | 0.76 | ABL1 (0.42) | ABL1MKNK2CDK8ABL2FGFR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10934275-B2 | IRE1 small molecule inhibitors | CORNELL UNIVERSITY (US) | 2021-03-02 | — | — | US | disclosed |
| US-20190276434-A1 | IRE1 Small Molecule Inhibitors | QUENTIS THERAPEUTICS, INC. (US) | 2019-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10934275-B2 | IRE1 small molecule inhibitors | XBP1, ERN2, ERN1 | ABL1 1855/4885MKNK2 631/4885CDK8 1861/4885 |
| US-20190276434-A1 | IRE1 Small Molecule Inhibitors | XBP1, ERN2, ERN1 | ABL1 1855/4885MKNK2 631/4885CDK8 1861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.